Search Results for "Policy"

Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.

A closer look at three of PhRMA’s most cited talking points.

Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.

Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.

Administrative Assistant, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Assistant Research Biostatistician, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Research Biostatistician, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Research Biostatistician, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

The US drug pricing system is broken, but not irreparable. For large-molecule biologic drugs, enter: Production Plus Profit Pricing (P-quad, pronounced like Ahab's seagoing vessel).

Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.

Peter Bach and Mark Trusheim's latest drug pricing idea: Have biologic innovators lower prices to "cost" plus a fixed (and generous) profit margin. The result? Huge financial savings for everyone.

How much would biologic drugs cost under P-quad pricing? Two approaches to estimating fully loaded costs plus a profit (10% and 20% examined) suggest net discounts from current prices would be at least 65% to 75%

The Drug Pricing Lab engaged Milliman to conduct an independent analysis of the Production Plus Profit Pricing (P-quad) policy proposal. The Milliman analysis estimates the projected spending on U.S. biologic and biosimilar drugs under a referent scenario where there is no biosimilar entry or competition, the existing ‘status quo’ scenario under the current biosimilar environment, and the Drug Pricing Lab’s P-quad policy proposal. 

This report was commissioned by Drug Pricing Lab.

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Senior Project Portfolio Manager, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Project Coordinator, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Qualitative Research Consultant, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Financial and Biopharma Industry Analyst, Drug Pricing Lab, Memorial Sloan Kettering Cancer Center

Program Director and Senior Health Economist, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center